Burden of alopecia areata in China, 1990–2021: Global Burden of Disease Study 2021

Abstract. Background:. Research has indicated that the disease burden of alopecia areata (AA) in China exceeds the global average. Therefore, accurate and updated epidemiological information is crucial for policymakers. In this study, we aimed to comprehensively assess the disease burden of AA in C...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiangqian Li, Huixin Liu, Wenhui Ren, Qijiong Zhu, Peng Yin, Lijun Wang, Jianzhong Zhang, Jinlei Qi, Cheng Zhou, Lishao Guo
Format: Article
Language:English
Published: Wolters Kluwer 2025-02-01
Series:Chinese Medical Journal
Online Access:http://journals.lww.com/10.1097/CM9.0000000000003373
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832585108285030400
author Xiangqian Li
Huixin Liu
Wenhui Ren
Qijiong Zhu
Peng Yin
Lijun Wang
Jianzhong Zhang
Jinlei Qi
Cheng Zhou
Lishao Guo
author_facet Xiangqian Li
Huixin Liu
Wenhui Ren
Qijiong Zhu
Peng Yin
Lijun Wang
Jianzhong Zhang
Jinlei Qi
Cheng Zhou
Lishao Guo
author_sort Xiangqian Li
collection DOAJ
description Abstract. Background:. Research has indicated that the disease burden of alopecia areata (AA) in China exceeds the global average. Therefore, accurate and updated epidemiological information is crucial for policymakers. In this study, we aimed to comprehensively assess the disease burden of AA in China. Methods:. The following four key indicators were utilized: the prevalence of cases; disability-adjusted life-years (DALYs); the age-standardized prevalence rate (ASPR); and the age-standardized DALY rate (ASDR) of AA according to the Global Burden of Disease (GBD) study 2021. We analyzed the epidemiological burden of AA in China during 2021, examined changes between 1990 and 2021, and performed a Bayesian age–period–cohort analysis to predict trends over the course of the next decade (2022–2030). Additionally, a Gaussian process regression model was applied to estimate the relationship between the gross domestic product (GDP) and the ASPR and ASDR of AA at the provincial level between 1992 and 2021. Results:. In 2021, the estimated number of patients with AA in China was approximately 3.49 million (95% uncertainty interval [UI], 3.37–3.62 million); of these patients, 1.20 million (95% UI, 1.16–1.25 million) were male and 2.29 million (95% UI, 2.20–2.37 million) were female. This large number of patients with AA resulted in a total of 114,431.25 DALYs (95% UI, 74,780.27–160,318.96 DALYs). Additionally, the ASPR and ASDR were 224.61 per 100,000 population (95% UI, 216.73–232.65 per 100,000 population) and 7.41 per 100,000 population (95% UI, 4.85–10.44 per 100,000 population), respectively; both of these rates were higher than the global averages. The most affected demographic groups were young and female individuals 25–39 years of age. Slight regional disparities were observed, with the northern and central regions of China bearing comparatively higher burdens. Between 1990 and 2021, the health loss and disease burden caused by AA in China remained relatively stable. The ASPR and ASDR of AA increased with the GDP when the annual GDP was less than 2 trillion Chinese yuan; however, a downward trend was observed as the GDP surpassed 2 trillion Chinese yuan. A slight upward trend in the disease burden of AA in China is predicted to occur over the next decade. Conclusions:. AA continues to be a public health concern in China that shows no signs of declining. Targeted efforts for young individuals and females are necessary because they experience a disproportionately high burden of AA.
format Article
id doaj-art-f3963afe007f40bc8c37c72eca375acd
institution Kabale University
issn 0366-6999
2542-5641
language English
publishDate 2025-02-01
publisher Wolters Kluwer
record_format Article
series Chinese Medical Journal
spelling doaj-art-f3963afe007f40bc8c37c72eca375acd2025-01-27T06:04:15ZengWolters KluwerChinese Medical Journal0366-69992542-56412025-02-01138331832410.1097/CM9.0000000000003373202502050-00010Burden of alopecia areata in China, 1990–2021: Global Burden of Disease Study 2021Xiangqian Li0Huixin Liu1Wenhui Ren2Qijiong Zhu3Peng Yin4Lijun Wang5Jianzhong Zhang6Jinlei Qi7Cheng Zhou8Lishao Guo1 Department of Dermatology, Peking University People’s Hospital, Beijing 100044, China2 Department of Clinical Epidemiology and Biostatistics, Peking University People’s Hospital, Beijing 100044, China2 Department of Clinical Epidemiology and Biostatistics, Peking University People’s Hospital, Beijing 100044, China3 Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, China4 National Center for Chronic and Non-Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China4 National Center for Chronic and Non-Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China1 Department of Dermatology, Peking University People’s Hospital, Beijing 100044, China4 National Center for Chronic and Non-Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China1 Department of Dermatology, Peking University People’s Hospital, Beijing 100044, ChinaAbstract. Background:. Research has indicated that the disease burden of alopecia areata (AA) in China exceeds the global average. Therefore, accurate and updated epidemiological information is crucial for policymakers. In this study, we aimed to comprehensively assess the disease burden of AA in China. Methods:. The following four key indicators were utilized: the prevalence of cases; disability-adjusted life-years (DALYs); the age-standardized prevalence rate (ASPR); and the age-standardized DALY rate (ASDR) of AA according to the Global Burden of Disease (GBD) study 2021. We analyzed the epidemiological burden of AA in China during 2021, examined changes between 1990 and 2021, and performed a Bayesian age–period–cohort analysis to predict trends over the course of the next decade (2022–2030). Additionally, a Gaussian process regression model was applied to estimate the relationship between the gross domestic product (GDP) and the ASPR and ASDR of AA at the provincial level between 1992 and 2021. Results:. In 2021, the estimated number of patients with AA in China was approximately 3.49 million (95% uncertainty interval [UI], 3.37–3.62 million); of these patients, 1.20 million (95% UI, 1.16–1.25 million) were male and 2.29 million (95% UI, 2.20–2.37 million) were female. This large number of patients with AA resulted in a total of 114,431.25 DALYs (95% UI, 74,780.27–160,318.96 DALYs). Additionally, the ASPR and ASDR were 224.61 per 100,000 population (95% UI, 216.73–232.65 per 100,000 population) and 7.41 per 100,000 population (95% UI, 4.85–10.44 per 100,000 population), respectively; both of these rates were higher than the global averages. The most affected demographic groups were young and female individuals 25–39 years of age. Slight regional disparities were observed, with the northern and central regions of China bearing comparatively higher burdens. Between 1990 and 2021, the health loss and disease burden caused by AA in China remained relatively stable. The ASPR and ASDR of AA increased with the GDP when the annual GDP was less than 2 trillion Chinese yuan; however, a downward trend was observed as the GDP surpassed 2 trillion Chinese yuan. A slight upward trend in the disease burden of AA in China is predicted to occur over the next decade. Conclusions:. AA continues to be a public health concern in China that shows no signs of declining. Targeted efforts for young individuals and females are necessary because they experience a disproportionately high burden of AA.http://journals.lww.com/10.1097/CM9.0000000000003373
spellingShingle Xiangqian Li
Huixin Liu
Wenhui Ren
Qijiong Zhu
Peng Yin
Lijun Wang
Jianzhong Zhang
Jinlei Qi
Cheng Zhou
Lishao Guo
Burden of alopecia areata in China, 1990–2021: Global Burden of Disease Study 2021
Chinese Medical Journal
title Burden of alopecia areata in China, 1990–2021: Global Burden of Disease Study 2021
title_full Burden of alopecia areata in China, 1990–2021: Global Burden of Disease Study 2021
title_fullStr Burden of alopecia areata in China, 1990–2021: Global Burden of Disease Study 2021
title_full_unstemmed Burden of alopecia areata in China, 1990–2021: Global Burden of Disease Study 2021
title_short Burden of alopecia areata in China, 1990–2021: Global Burden of Disease Study 2021
title_sort burden of alopecia areata in china 1990 2021 global burden of disease study 2021
url http://journals.lww.com/10.1097/CM9.0000000000003373
work_keys_str_mv AT xiangqianli burdenofalopeciaareatainchina19902021globalburdenofdiseasestudy2021
AT huixinliu burdenofalopeciaareatainchina19902021globalburdenofdiseasestudy2021
AT wenhuiren burdenofalopeciaareatainchina19902021globalburdenofdiseasestudy2021
AT qijiongzhu burdenofalopeciaareatainchina19902021globalburdenofdiseasestudy2021
AT pengyin burdenofalopeciaareatainchina19902021globalburdenofdiseasestudy2021
AT lijunwang burdenofalopeciaareatainchina19902021globalburdenofdiseasestudy2021
AT jianzhongzhang burdenofalopeciaareatainchina19902021globalburdenofdiseasestudy2021
AT jinleiqi burdenofalopeciaareatainchina19902021globalburdenofdiseasestudy2021
AT chengzhou burdenofalopeciaareatainchina19902021globalburdenofdiseasestudy2021
AT lishaoguo burdenofalopeciaareatainchina19902021globalburdenofdiseasestudy2021